What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GHRH analog · approved for HIV-associated lipodystrophy
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating Tesamorelin through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Tesamorelin is a 44-residue synthetic GHRH analogue carrying an N-terminal trans-3-hexenoyl modification that blocks DPP-4 cleavage and extends plasma half-life well beyond native GHRH or unmodified Sermorelin. It stands as the only FDA-approved member of the GHRH-analogue class, marketed as Egrifta for HIV-associated lipodystrophy, with the approved label specifically covering reduction of excess visceral abdominal adipose tissue in lipodystrophic HIV-positive patients. For compounding pharmacy buyers, Vialdyne releases Tesamorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. At 44 residues, the sequence sits at the upper-middle of routine SPPS, and the release packet centres on peak-integration RP-HPLC plus ESI-MS confirming the N-terminal hexenoyl-modified mass, which is the diagnostic identity check. LC-MS/MS sequence verification is the qualification add-on we recommend at first-time pharmacy onboarding, the positional integrity of the hexenoyl group is load-bearing for biological activity, and intact-mass spec alone cannot localise the modification with complete confidence. Most catalogue volume moves as the standalone Tesamorelin vial for visceral-fat compounding and research, or as the pre-blended co-lyophilised Tesamorelin-plus-Ipamorelin presentation under the tesa-ipa-blend SKU for dual-pathway GH-axis preparations.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Tesamorelin, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Tesamorelin
VD260428-TSM10200 · 98.94%
VerifiedRequest full COA →Tesamorelin
VD260428-TSM20201 · 98.95%
VerifiedRequest full COA →Tesamorelin
VD260428-TSM198 · 99.12%
VerifiedRequest full COA →Tesamorelin
VD260428-TSM5199 · 99.45%
Regulatory note
Under the brand name Egrifta, the finished Tesamorelin drug carries FDA approval for HIV-associated lipodystrophy. On its own, however, the active does not appear on the 503A bulks list, and whether it can be compounded for off-label or other indications turns on the destination market's regulatory posture and shortage status at the time.
Selected literature
Frequently asked questions
Keep the sealed vial frozen at -20 C, protected from moisture, where the hexenoyl-modified peptide follows a 24-month re-test schedule with the exact date documented on the released-batch certificate. The N-terminal trans-3-hexenoyl group improves protease resistance in circulation but does not change cold-storage discipline in the vial, so treat freeze-thaw exposure as the operative stability variable once material is in hand. Cold-chain integrity during transit belongs in the receiving record as well, since a documented temperature excursion is the kind of event that would trigger an out-of-schedule potency re-check before release to compounding.
Reconstitute the lyophilised powder in bacteriostatic water for injection at a working concentration, and because the finished preparation is injectable, do the reconstitution inside a sterile field. Draw the smallest workable single-use aliquots immediately after dissolution, since freeze-thaw cycle count is the dominant contributor to measured-potency loss for this class while gradual temperature drift matters much less. Cap cumulative thaws at three or fewer per aliquot and store at -20 C. When co-blending with a GHSR agonist under the tesa-ipa-blend SKU, work from the pre-lyophilised combination vial rather than mixing separately reconstituted components at the bench.
Related peptides
29-mer
GHRH 1-29 fragment
Modified GRF 1-29 · GHRH analog
GH-axis blend (Tesamorelin + Ipamorelin), 15 mg total
